ReviewBiofabrication2025
3D bioprinting in tissue engineering: current state-of-the-art and challenges towards system standardization and clinical translation.
Review in Biofabrication, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Three-Dimensional Bioprinting in Reconstructive Plastic Surgery: A Comprehensive Review.Cells · 2026Review
- Advances in 3D Bioprinting for Scaffold-Based and Scaffold-Free Tissue Engineering and Regenerative Medicine.Gels (Basel, Switzerland) · 2026Review
- Multiscale biomimetic design for peripheral nerve repair: Beyond passive bridging.Materials today. Bio · 2026Review
- Simple fabrication method for cancer cell migration studies on biomimetic substrates with tunable stiffness.Materials today. Bio · 2026Article
- Computational approaches in bioprinting processes.Nature reviews bioengineering · 2026Article
- A Narrative Review of Advances in Skin Tissue Engineering: From Physiological Architecture to 3D Bioprinting.Cureus · 2026Review
- From Technological Innovation to Clinical Translation: Progress and Challenges in 3D Bioprinting for the Development of Breast Cancer Bone Metastasis Models.Advanced healthcare materials · 2026Review
- Organoids: From Bench to Bedside Applications.MedComm · 2026Review
- From bone replacement to regeneration. A biomaterials started journey.Materials today. Bio · 2026Review
- 3D bioprinted in vitro models in cancer metabolism research.Magyar onkologia · 2026Review
- Biopolymer-Nanoparticle Interactions in 3D-Printing for Biomedical Applications: Advantages, Limitations and Future Perspectives.Polymers · 2026Review
- Structure-Property-Function Relationships in Stimuli-Responsive Hydrogels for Brain Organoid Vascularization.Gels (Basel, Switzerland) · 2026Review
- Design and Fabrication of Biomimetic Gradient Bone Tissue Engineering Scaffolds: Evolution from Single-Gradient to Multi-Gradient.Gels (Basel, Switzerland) · 2026Review
- Self-driving bioprinting laboratories.Biofabrication · 2026Review
- Integrative bioengineering strategies for endometrial regeneration: From biomaterials and stem cells to organoids and organ-on-a-chip technologies.Theranostics · 2026Review
- Harnessing Advances in Bone Tissue Engineering for Design of Bone-on-Chip Systems.Advanced healthcare materials · 2026Review
- Review
- 3D Bioprinting Strategies in Autoimmune Disease Models.International journal of molecular sciences · 2025Review
- Current status, trend and progress of stem cells in tracheal tissue engineering research: an overview and perspectives.Stem cell research & therapy · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Over the past decade, three-dimensional (3D) bioprinting has made significant progress, transforming into a key innovation in tissue engineering. Despite the early strides, critical challenges remain in 3D bioprinting that must be addressed to accelerate clinical translation. In particular, there is still a long way to go before functionally-mature, clinically-relevant tissue equivalents are developed. Current limitations range from the sub-optimal bioink properties and degree of biomimicry of bioprintable architectures, to the lack of stem/progenitor cells for massive cell expansion, and fundamental knowledge regarding
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.